Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol

Slides:

Advertisements

Similar presentations

House dust mite avoidance measures improve peak flow and symptoms in patients with allergy but without asthma: A possible delay in the manifestation of.

Advertisements

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Mite allergen (Der p 1) concentration in houses and its relation to the presence and severity of asthma in a population of Sydney schoolchildren Guy.

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Richard L. ZuWallack, MD a,b, James P

Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma Patrick Booms, MSca, David.

Rosa Codina, PhD, Richard F. Lockey, MD

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Practice Notes from the AAAI

Badrul A. Chowdhury, MD, PhD

Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma B.Lauren Charous, MD, Elkan F. Halpern,

Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma Annika Wallin, PhDa, Malcolm Sue-Chu, PhDb, Leif Bjermer,

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

Edwin A. Bronsky, MD, Howard Druce, MD, Steven R. Findlay, MD, Frank C

Elephantiasis nostras: A case report

The impact of allergic rhinitis on bronchial asthma

Conjunctivitis medicamentosa

Treatment of chronic autoimmune urticaria with omalizumab

Nonadherence to Asthma Treatment: Getting Unstuck

Side effects of inhaled corticosteroids

Jaring S. van der Zee, a, Koos S. N. de Jager, b, Bart F

Practice Notes from the AAAAI

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations John H. Toogood, MD,

Robert A. Wood, MD, Wanda Phipatanakul, MD, Robert G

A review of the current guidelines for allergic rhinitis and asthma

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Early decreases in blood eosinophil levels with reslizumab

Physician-targeted program on inhaled therapy for childhood asthma

News & Notes Journal of Allergy and Clinical Immunology

James P. Kemp, MDa, David A. Cook, MDb, Gary A

Circadian variation of sputum inflammatory cells in mild asthma

Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization Qutayba Hamid, MD, PhD, Editor Journal.

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.

Wine-induced asthma: A placebo-controlled assessment of its pathogenesis Hassan Vally, BSc (Hons), Amanda Carr, BAppSc, Jacque El-Saleh, RN, Philip Thompson,

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer.

Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses Raul E. Melo, MD, Dirceu Solé,

Peter S. Creticos, MD Journal of Allergy and Clinical Immunology

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Autophagy: Nobel Prize 2016 and allergy and asthma research

News & Notes Journal of Allergy and Clinical Immunology

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.

Clinical effects of nedocromil sodium on challenges invoking neuronal mechanisms and on virally induced symptoms Peter König, MD, PhD Journal of Allergy.

Exercise-induced asthma: Is it the right diagnosis in elite athletes?

Preparing patients and health professionals for the transition to chlorofluorocarbon-free inhalers: The British perspective Helen Donohoe, MSc (Econ)

Practice Notes from the AAAI

Leukotriene receptor antagonists in asthma therapy

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

Nitric oxide as a clinical guide for asthma management

Changes in sputum counts and airway hyperresponsiveness after budesonide: Monitoring anti-inflammatory response on the basis of surrogate markers of airway.

Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy Diane J. Pincus, MD, Teresa R. Humeston,

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Effect of continuing or finishing high-level sports on airway inflammation, bronchial hyperresponsiveness, and asthma: A 5-year prospective follow-up.

Footnotes1 Journal of Allergy and Clinical Immunology

Prescott G. Woodruff, MD, MPH, Ramin Khashayar, MD, Stephen C

Macrolide antibiotics and asthma treatment

Larry C. Borish, MDa, Harold S

Exhaled carbon monoxide levels after a course of oral prednisone in children with asthma exacerbation Stefania Zanconato, MD, PhD, Massimo Scollo, MD,

The preventive effect and duration of action of two doses of inhaled furosemide on exercise-induced asthma in children Elio Novembre, MD, Gianfranco.

Bruce K. Bacot, MD, Mary E. Paul, MD, Maritza Navarro, MD, Stuart L

News & Notes Journal of Allergy and Clinical Immunology

Presentation transcript:

Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol Stephen I. Wasserman, MD, Clifton T. Furukawa, MD, Stuart I. Henochowicz, MD, J.Paul Marcoux, MD, Bruce M. Prenner, MD, Steven R. Findlay, MD, Garry N. Gross, MD, Leonard D. Hudson, MD, Debra J. Myers, MD, Paul Steinberg, MD Journal of Allergy and Clinical Immunology Volume 95, Issue 2, Pages 541-547 (February 1995) DOI: 10.1016/S0091-6749(95)70316-0 Copyright © 1995 Mosby, Inc. Terms and Conditions

FIG. 1 Mean asthma symptom scores (± SEM) during 12 weeks of treatment with nedocromil sodium (solid line) and albuterol (dashed line) . Mean symptom scores over the final 10 weeks of treatment (weeks 3 to 12) are also shown. BL, Baseline. Significant between-treatment differences have been marked: *p < 0.05, **p < 0.01, *** p < 0.001. Journal of Allergy and Clinical Immunology 1995 95, 541-547DOI: (10.1016/S0091-6749(95)70316-0) Copyright © 1995 Mosby, Inc. Terms and Conditions

FIG. 1 Mean asthma symptom scores (± SEM) during 12 weeks of treatment with nedocromil sodium (solid line) and albuterol (dashed line) . Mean symptom scores over the final 10 weeks of treatment (weeks 3 to 12) are also shown. BL, Baseline. Significant between-treatment differences have been marked: *p < 0.05, **p < 0.01, *** p < 0.001. Journal of Allergy and Clinical Immunology 1995 95, 541-547DOI: (10.1016/S0091-6749(95)70316-0) Copyright © 1995 Mosby, Inc. Terms and Conditions

FIG. 1 Mean asthma symptom scores (± SEM) during 12 weeks of treatment with nedocromil sodium (solid line) and albuterol (dashed line) . Mean symptom scores over the final 10 weeks of treatment (weeks 3 to 12) are also shown. BL, Baseline. Significant between-treatment differences have been marked: *p < 0.05, **p < 0.01, *** p < 0.001. Journal of Allergy and Clinical Immunology 1995 95, 541-547DOI: (10.1016/S0091-6749(95)70316-0) Copyright © 1995 Mosby, Inc. Terms and Conditions

FIG. 1 Mean asthma symptom scores (± SEM) during 12 weeks of treatment with nedocromil sodium (solid line) and albuterol (dashed line) . Mean symptom scores over the final 10 weeks of treatment (weeks 3 to 12) are also shown. BL, Baseline. Significant between-treatment differences have been marked: *p < 0.05, **p < 0.01, *** p < 0.001. Journal of Allergy and Clinical Immunology 1995 95, 541-547DOI: (10.1016/S0091-6749(95)70316-0) Copyright © 1995 Mosby, Inc. Terms and Conditions

FIG. 2 Mean morning, evening, and diurnal variation in PEFR (± SEM) during 12 weeks of treatment with nedocromil sodium (solid line) and albuterol (dashed line). Mean values over the final 10 weeks of treatment (weeks 3 to 12) are also shown. BL, Baseline. Significant between-treatment differences have been marked: *p < 0.05, **p < 0.01, ***p < 0.001. Journal of Allergy and Clinical Immunology 1995 95, 541-547DOI: (10.1016/S0091-6749(95)70316-0) Copyright © 1995 Mosby, Inc. Terms and Conditions

FIG. 2 Mean morning, evening, and diurnal variation in PEFR (± SEM) during 12 weeks of treatment with nedocromil sodium (solid line) and albuterol (dashed line). Mean values over the final 10 weeks of treatment (weeks 3 to 12) are also shown. BL, Baseline. Significant between-treatment differences have been marked: *p < 0.05, **p < 0.01, ***p < 0.001. Journal of Allergy and Clinical Immunology 1995 95, 541-547DOI: (10.1016/S0091-6749(95)70316-0) Copyright © 1995 Mosby, Inc. Terms and Conditions

FIG. 2 Mean morning, evening, and diurnal variation in PEFR (± SEM) during 12 weeks of treatment with nedocromil sodium (solid line) and albuterol (dashed line). Mean values over the final 10 weeks of treatment (weeks 3 to 12) are also shown. BL, Baseline. Significant between-treatment differences have been marked: *p < 0.05, **p < 0.01, ***p < 0.001. Journal of Allergy and Clinical Immunology 1995 95, 541-547DOI: (10.1016/S0091-6749(95)70316-0) Copyright © 1995 Mosby, Inc. Terms and Conditions

FIG. 3 Mean clinic measurement of FEV 1 (± SEM) during 12 weeks of treatment with nedocromil sodium (solid line) and albuterol (dashed line). Mean FEV 1 over the final four clinic visits (10 weeks of treatment) is also shown. BL, Baseline. There were no significant between-treatment differences. Journal of Allergy and Clinical Immunology 1995 95, 541-547DOI: (10.1016/S0091-6749(95)70316-0) Copyright © 1995 Mosby, Inc. Terms and Conditions